• Скринінг і тактика тяжких менструальних кровотеч у підлітків із дефектами у системі гемостазу
ua До змісту

Скринінг і тактика тяжких менструальних кровотеч у підлітків із дефектами у системі гемостазу

HEALTH OF WOMAN. 2019.8(144): 93–102
Дана концепція експертів була розроблена Комітетом з Охорони здоров’я підлітків Американського коледжу акушерів та гінекологів у співпраці з членами комітету Oluyemisi Adeyemi-Fowode, MD та Judith Simms-Cendan, MD.
Погляд комітету експертів Американського коледжу акушерів та гінекологів
Номер 785. – Комітет з Охорони здоров’я підлітків

Адаптовано Л.В. Пахаренко
СПИСОК ЛІТЕРАТУРИ

1. National Institute for Health and Care Excellence. Heavy menstrual bleeding: assessment and management. London (UK): NICE; 2018. Available at: https://www.nice.org.uk/guidance/ng88. Retrieved January 7, 2019.

2. Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. Committee Opinion No. 557. American College of Obstetricians and Gynecologists. Obstet Gynecol 2013;121:891–6.

3. Venkateswaran L, Dietrich JE. Gynecologic concerns in pubertal females with blood disorders. J Pediatr Adolesc Gynecol 2013;26:80–5.

4. Haamid F, Sass AE, Dietrich JE. Heavy menstrual bleeding in adolescents. J Pediatr Adolesc Gynecol 2017;30:335–40.

5. Smith YR, Quint EH, Hertzberg RB. Menorrhagia in adolescents requiring hospitalization. J Pediatr Adolesc Gynecol 1998;11:13–5.

6. Hurwitz A, Massone R, Lopez BL. Acquired bleeding disorders. Hematol Oncol Clin North Am 2017;31:1123–45.

7. Dowlut-McElroy T, Williams KB, Carpenter SL, Strickland JL. Menstrual patterns and treatment of heavy menstrual bleeding in adolescents with bleeding disorders. J Pediatr Adolesc Gynecol 2015;28:499–501.

8. Mikhail S, Kouides P. von Willebrand disease in the pediatric and adolescent population. J Pediatr Adolesc Gynecol 2010;23(suppl 6):S3–10.

9. Byams VR, Kouides PA, Kulkarni R, Baker JR, Brown DL, Gill JC, et al. Surveillance of female patients with inherited bleeding disorders in United States haemophilia treatment centres. Haemophilia Treatment Centres Network Investigators. Haemophilia 2011;17(suppl 1):6–13.

10. Diaz R, Dietrich JE, Mahoney D Jr, Yee DL, Srivaths LV. Hemostatic abnormalities in young females with heavy menstrual bleeding. J Pediatr Adolesc Gynecol 2014;27:324–9.

11. Bruner AB, Joffe A, Duggan AK, Casella JF, Brandt J. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet 1996;348:992–6.

12. Falkingham M, Abdelhamid A, Curtis P, Fairweather-Tait S, Dye L, Hooper L. The effects of oral iron supplementation on cognition in older children and adults: a systematic review and meta-analysis. Nutr J 2010;9:4.

13. Johnson S, Lang A, Sturm M, O’Brien SH. Iron deficiency without anemia: a common yet under-recognized diagnosis in young women with heavy menstrual bleeding. J Pediatr Adolesc Gynecol 2016;29:628–31.

14. El-Nashar SA, Shazly SA. Pictorial blood loss assessment chart for quantification of menstrual blood loss: a systematic review. Gynecol Surg 2015;12:157–63.

15. Sekhar DL, Murray-Kolb LE, Kunselman AR, Paul IM. Identifying factors predicting iron deficiency in United States adolescent females using the ferritin and the body iron models. Clin Nutr ESPEN 2015;10:e118–23.

16. Powers JM, Buchanan GR. Diagnosis and management of iron deficiency anemia. Hematol Oncol Clin North Am 2014;28:729–45, vi–vii.

17. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. Centers for Disease Control and Prevention [published erratum appears in MMWR Recomm Rep. 2015;64:924]. MMWR Recomm Rep 2015; 64(RR-03):1–137.

18. Pecchioli Y, Oyewumi L, Allen LM, Kives S. The utility of routine ultrasound in the diagnosis and management of adolescents with abnormal uterine bleeding. J Pediatr Adolesc Gynecol 2017;30:239–42.

19. Diagnosis of abnormal uterine bleeding in reproductiveaged women. Practice Bulletin No. 128. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012; 120:197–206.

20. Tranexamic acid oral. In: Facts & Comparisons [after login]. St. Louis (MO): Wolters Kluwer Health, Inc; 2019. Available at: http://fco.factsandcomparisons.com/lco/action/home. Retrieved May 20, 2019.

21. Chi C, Pollard D, Tuddenham EG, Kadir RA. Menorrhagia in adolescents with inherited bleeding disorders. J Pediatr Adolesc Gynecol 2010;23:215–22.

22. Thorne JG, James PD, Reid RL. Heavy menstrual bleeding: is tranexamic acid a safe adjunct to combined hormonal contraception [commentary]? Contraception 2018;98:1–3.

23. Napolitano LM, Kurek S, Luchette FA, Anderson GL, Bard MR, Bromberg W, et al. Clinical practice guideline: red blood cell transfusion in adult trauma and critical care. EAST Practice Management Workgroup, American College of Critical Care Medicine (ACCM), Taskforce of the Society of Critical Care Medicine (SCCM). J Trauma 2009; 67:1439–42.

24. Parker RI. Transfusion in critically ill children: indications, risks, and challenges. Crit Care Med 2014;42:675–90.

25. Carson JL, Stanworth SJ, Roubinian N, Fergusson DA, Triulzi D, Doree C, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database of Systematic Reviews 2016, Issue 10. Art. No.: CD002042. DOI: 10.1002/14651858.CD002042. pub4.

26. Revert M, Rozenberg P, Cottenet J, Quantin C. Intrauterine balloon tamponade for severe postpartum hemorrhage. Obstet Gynecol 2018;131:143–9.

27. Halimeh S. Menorrhagia and postpartum haemorrhage in women with rare bleeding disorder. Thromb Res 2015; 135(suppl 1):S34–7.

28. James AH, Kouides PA, Abdul-Kadir R, Dietrich JE, Edlund M, Federici AB, et al. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol 2011;158:124–34.

29. Hamani Y, Ben-Shachar I, Kalish Y, Porat S. Intrauterine balloon tamponade as a treatment for immune thrombocytopenic purpura-induced severe uterine bleeding. Fertil Steril 2010;94:2769.e13–5.

30. Handa VL, Le LV. Te Linde’s atlas of gynecologic surgery. 12th ed. Philadelphia (PA): Wolters Kluwer; 2019.

31. Davies J, Kadir RA. Heavy menstrual bleeding: an update on management. Thromb Res 2017;151(suppl 1):S70–7.

32. Kuhnz W, Heuner A, Humpel M, Seifert W, Michaelis K. In vivo conversion of norethisterone and norethisterone acetate to ethinyl etradiol in postmenopausal women. Contraception 1997;56:379–85.

33. Levonorgestrel-releasing intrauterine system (52 mg) for idiopathic heavy menstrual bleeding: a health technology assessment. Health Quality Ontario. Ont Health Technol Assess Ser 2016;16:1–119.

34. Gupta JK, Daniels JP, Middleton LJ, Pattison HM, Prileszky G, Roberts TE, et al. A randomised controlled trial of the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia: the ECLIPSE trial. ECLIPSE Collaborative Group. Health Technol Assess 2015;19:i–xxv, 1–118.

35. Shaaban MM, Zakherah MS, El-Nashar SA, Sayed GH. Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial [published erratum appears in Contraception 2011;84:112]. Contraception 2011;83:48–54.

36. Endrikat J, Shapiro H, Lukkari-Lax E, Kunz M, Schmidt W, Fortier M. A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. J Obstet Gynaecol Can 2009;31:340–7.

37. Irvine GA, Campbell-Brown MB, Lumsden MA, Heikkila A, Walker JJ, Cameron IT. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 1998;105:592–8.

38. Lukes AS, Reardon B, Arepally G. Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders. Fertil Steril 2008;90:673–7.

39. Kingman CE, Kadir RA, Lee CA, Economides DL. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG 2004;111:1425–8.

40. Schaedel ZE, Dolan G, Powell MC. The use of the levonorgestrel-releasing intrauterine system in the management of menorrhagia in women with hemostatic disorders. Am J Obstet Gynecol 2005;193:1361–3.

41. Chi C, Huq FY, Kadir RA. Levonorgestrel-releasing intrauterine system for the management of heavy menstrual bleeding in women with inherited bleeding disorders: long-term follow-up. Contraception 2011;83: 242–7.

42. Silva CD, Geraldes F, Silva IS. Levonorgestrel intrauterine system as a treatment option for severe menorrhagia in adolescent with type III von Willebrand disease. BMJ Case Rep 2013; 2013:bcr2013008833.

43. Stalnaker M, Esquivel P. Managing menorrhagia in a familial case of factor V deficiency. J Pediatr Adolesc Gynecol 2015;28:e9–12.

44. Counseling adolescents about contraception. Committee Opinion No. 710. American College of Obstetricians and Gynecologists. Obstet Gynecol 2017;130:e74–80.

45. Adeyemi-Fowode OA, Santos XM, Dietrich JE, Srivaths L. Levonorgestrel-releasing intrauterine device use in female adolescents with heavy menstrual bleeding and bleeding disorders: single institution review. J Pediatr Adolesc Gynecol 2017;30:479–83.

46. McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993–2005. Public Health Nutr 2009;12:444–54.

47. Centers for Disease Control and Prevention, (CDC). Iron deficiency—United States, 1999–2000. MMWR Morb Mortal Wkly Rep 2002;51:897–9.

48. Cooke AG, McCavit TL, Buchanan GR, Powers JM. Iron deficiency anemia in adolescents who present with heavy menstrual bleeding. J Pediatr Adolesc Gynecol 2017;30: 247–50.

49. Powers JM, McCavit TL, Buchanan GR. Management of iron deficiency anemia: a survey of pediatric hematology/oncology specialists. Pediatr Blood Cancer 2015;62: 842–6.

50. Hagan JF, Shaw JS, Duncan PM. Bright futures: guidelines for health supervision of infants, children, and adolescents, 4th ed. Elk Grove Village (IL): American Academy of Pediatrics; 2017.

51. Recommendations to prevent and control iron deficiency in the United States. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998;47(RR-3):1–29.

52. Anemia in pregnancy. ACOG Practice Bulletin No. 95. American College of Obstetricians and Gynecologists. Obstet Gynecol 2008;112:201–7.

53. Moretti D, Goede JS, Zeder C, Jiskra M, Chatzinakou V, Tjalsma H, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood 2015;126: 1981–9.

54. Stoffel NU, Cercamondi CI, Brittenham G, Zeder C, Geurts-Moespot AJ, Swinkels DW, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twicedaily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol 2017;4: e524–33.

55. Jarvis RR, Olsen ME. Type I von Willebrand’s disease presenting as recurrent corpus hemorrhagicum. Obstet Gynecol 2002;99:887–8.

56. Radakovic B, Grgic O. Von Willebrand disease and recurrent hematoperitoneum due to the rupture of haemorrhagic ovarian cysts. Haemophilia 2009;15: 607–9.

57. Ahuja SP, Hertweck SP. Overview of bleeding disorders in adolescent females with menorrhagia. J Pediatr Adolesc Gynecol 2010;23(suppl 6):S15–21.

58. Kirtava A, Drews C, Lally C, Dilley A, Evatt B. Medical, reproductive and psychosocial experiences of women diagnosed with von Willebrand’s disease receiving care in haemophilia treatment centres: a case-control study. Haemophilia 2003;9:292–7.

59. James AH. More than menorrhagia: a review of the obstetric and gynaecological manifestations of von Willebrand disease. Thromb Res 2007;120(suppl 1):S17–20.

60. The initial reproductive health visit. Committee Opinion No. 598. American College of Obstetricians and Gynecologists. Obstet Gynecol 2014;123:1143–7.

61. Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Committee Opinion No. 651. American College of Obstetricians and Gynecologists. Obstet Gynecol 2015;126:e143–6.

62. National Institutes of Health. The diagnosis, evaluation, and management of von Willebrand Disease. Bethesda (MD): NIH; 2007. Available at: https://www.nhlbi.nih.gov/files/docs/ guidelines/vwd.pdf. Retrieved February 7, 2019.

63. National Heart, Lung, and Blood Institute. Available at: https://www.nhlbi.nih.gov/. Retrieved February 6, 2019.

64. National Hemophilia Foundation. Available at: www.hemophilia.org/. Retrieved January 7, 2019.

65. Hemophilia Federation of America. Available at: www.hemophiliafed.org/. Retrieved February 6, 2019.

66. Foundation for Women and Girls with Blood Disorders. Available at: http://www.fwgbd.org/. Retrieved February 6, 2019.

67. American Society of Hematology. Available at: http://www.hematology.org/. Retrieved February 6, 2019.